Ginkgo Bioworks Holdings, Inc.
DNA
$6.82
$0.131.94%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -25.06% | -17.13% | 25.21% | 13.76% | -9.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -25.06% | -17.13% | 25.21% | 13.76% | -9.71% |
| Cost of Revenue | 5.44% | 18.67% | 33.02% | 16.07% | -17.51% |
| Gross Profit | -32.50% | -25.57% | 23.29% | 13.20% | -7.57% |
| SG&A Expenses | -23.90% | -25.47% | -30.70% | -28.59% | -30.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.18% | -33.10% | -39.53% | -30.71% | -27.85% |
| Operating Income | 37.01% | 39.52% | 57.08% | 44.08% | 34.08% |
| Income Before Tax | 42.72% | 47.81% | 64.79% | 44.67% | 38.68% |
| Income Tax Expenses | -74.74% | -47.44% | -89,600.00% | -245.90% | -574.65% |
| Earnings from Continuing Operations | 42.83% | 47.86% | 64.89% | 44.71% | 38.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.83% | 47.86% | 64.89% | 44.71% | 38.73% |
| EBIT | 37.01% | 39.52% | 57.08% | 44.08% | 34.08% |
| EBITDA | 39.74% | 42.32% | 60.07% | 45.91% | 33.86% |
| EPS Basic | 46.85% | 51.74% | 67.53% | 48.34% | 42.17% |
| Normalized Basic EPS | 39.43% | 41.32% | 60.20% | 47.59% | 38.18% |
| EPS Diluted | 46.83% | 51.76% | 67.54% | 48.38% | 42.20% |
| Normalized Diluted EPS | 39.42% | 41.30% | 60.19% | 47.58% | 38.17% |
| Average Basic Shares Outstanding | 6.88% | 7.57% | 7.74% | 7.63% | 6.75% |
| Average Diluted Shares Outstanding | 6.86% | 7.54% | 7.72% | 7.61% | 6.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |